Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Epizyme Earns $10M GSK Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Epizyme Earns $10M GSK Milestone

Initiates GLP tox studies with novel methyltransferase inhibitor

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Epizyme, Inc., a clinical-stage biopharma company developing epigenetic therapies, has earned a $10 million milestone payment from GlaxoSmithKline (GSK). The payment follows GSK’s initiation of GLP toxicology studies for a first-in-class methyltransferase inhibitor discovered by Epizyme and licensed to GSK.

“We are pleased to achieve another milestone under our collaboration with GSK, further validating the strength of our epigenetic approach and drug discovery platform, as well our success in collaborating with industry leaders like GSK,” said Susan Graf, chief business officer of Epizyme. “We are encouraged that this investigational medicine continues to advance toward the clinic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics